Publications by Alan Nicolas Thierry Guichard

Trajectories of macrophage ontogeny and reprogramming in cancer

Michele De Palma, Nahal Mansouri, Céline Wyser Rmili, Gael Luis Boivin, Alan Nicolas Thierry Guichard

Tumor-associated macrophages (TAMs) often manifest immunosuppressive and tumor-promoting phenotypes contributing to immunotherapy resistance. Dicer1 inactivation in TAMs (DKO) prompts their immunostimulatory activation, enabling effective immunotherapy in ...

2025

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Michele De Palma, Nahal Mansouri, Ali Ghasemi, Bruno Torchia, Yahya Mohammadzadeh, Alan Nicolas Thierry Guichard

Dendritic cells (DCs) are antigen-presenting myeloid cells that regulate T cell activation, trafficking and function. Monocyte-derived DCs pulsed with tumor antigens have been tested extensively for therapeutic vaccination in cancer, with mixed clinical re ...

Nature Portfolio2023

Determinants of tumor resistance to anti-angiogenic immunotherapy in mouse models of Kras-mutant NSCLC

Michele De Palma, Bruno Torchia, Etienne Meylan, Chiara Cianciaruso, Sina Nassiri, Ioanna Keklikoglou, Ece Kadioglu, Amaia Martinez Usatorre, Alan Nicolas Thierry Guichard

AMER ASSOC CANCER RESEARCH2021

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Michele De Palma, Nadine Fournier, Bruno Torchia, Etienne Meylan, Chiara Cianciaruso, Sina Nassiri, Ioanna Keklikoglou, Ece Kadioglu, Gael Luis Boivin, Amaia Martinez Usatorre

Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of nonsmall cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic d ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

Michele De Palma, Nicolo Rigamonti, Alan Nicolas Thierry Guichard, Daniela Pais Ferreira

Cancer immunotherapies are increasingly combined with targeted therapies to improve therapeutic outcomes. We show that combination of agonistic anti-CD40 with antiangiogenic antibodies targeting 2 proangiogenic factors, vascular endothelial growth factor A ...

2020

Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

Matthias Lütolf, Michele De Palma, Mario Leonardo Squadrito, Mauro Delorenzi, Sina Nassiri, Alan Nicolas Thierry Guichard, Nikolche Gjorevski, Simone Ragusa, Borja Prat Luri, Laureline Wetterwald

Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential respon ...

2020

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

Ioanna Keklikoglou, Michele De Palma, Mario Leonardo Squadrito, Chiara Cianciaruso, Esra Güç, Alan Nicolas Thierry Guichard, Antonino Cassarà

Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental studies in mice also suggest that chemotherapy has pro-metastatic effects. Primary tumours release extracellular vesicles (EVs), including exosomes, that can ...

2019